Vous avez cherché: thrombocythaemia (Anglais - Danois)

thrombocythaemia
thrombocytæmi

thrombocythaemia, anaemia, eosinophilia
blod - og lymfesystem ikke almindelig: trombocytæmi, anæmi, eosinofili

uncommon: thrombocythaemia, leukocytosis.
ikke almindelig: trombocytæmi, leukocytose.

treatment of essential thrombocythaemia
treatment of essential thrombocythaemia

thrombocythaemia splenomegaly lymphadenopathy hypochromasia
trombocytæmi splenomegali lymfadenopati hypokromasi

ris intracranial/intracerebral) , thrombocythaemia
immunsystemetmetabolisme og ernæring nervesystemet

thrombocythaemia (incl. platelet count increased)
stigning i konjungeret bilirubin (med eller uden samtidig stigning i alat)

thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy
trombocytæmi, lymfopeni, knoglemarvsdepression, eosinofili, lymfadenopati

thrombocytopenia, purpura, thrombocythaemia, platelet abnormal, coagulation disorder
hæmatom) , trombocytopeni, purpura, trombocytæmi, trombocytabnormitet, koagulationsforstyrrelse er

for this reason it is used to treat patients with essential thrombocythaemia.
derfor anvendes det til behandling af patienter med essentiel trombocytæmi.

thrombocytopenia, purpura, thrombocythaemia, platelet abnormal, coagulation disorder ro lp
immunsystemet

· at the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide
· ved de doser, der anbefales til brug ved behandling af essentiel trombocytæmi, kan anagrelid

an at risk essential thrombocythaemia patient is defined by one or more of the following features:
en patient i risikogruppe for essentiel trombocytæmi defineres ved hjælp af én eller flere af følgende egenskaber:

rare: other bleeding (hepatic, retroperitoneal, intracranial/intracerebral), thrombocythaemia
sjælden: andre blødninger (hepatiske, retroperitoneale, intrakranielle/intracerebrale), trombocytæmi

treatment with xagrid should only be started by a doctor who has experience in the treatment of essential thrombocythaemia.
behandling med xagrid bør kun iværksættes af en læge med kendskab til behandling af essentiel trombocytæmi.

essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets.
essentiel trombocytæmi er en tilstand, der optræder, når knoglemarven producerer for mange af de blodceller, der kaldes blodplader.

in patients with essential thrombocythaemia complete response was defined as a decrease in platelet count to  600 x 109/l or a
hos patienter med essentiel trombocytæmi blev komplet respons defineret som et fald i blodpladetallet til

neutropenia, thrombocytopenia, anaemia pancytopenia, febrile neutropenia thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy
neutropeni, thrombocytopeni, anæmi pancytopeni, febril neutropeni trombocytæmi, lymfopeni, knoglemarvsdepression, eosinofili, lymphadenopati hæmolytisk anæmi

they decided that xagrid’ s benefits are greater than its risks as second-line treatment in at risk patients with essential thrombocythaemia.
udvalget fandt, at fordelene ved xagrid opvejer risiciene som andetvalgsbehandling af udsatte patienter med essentiel trombocytæmi.

a phase iiib, randomised study to compare the efficacy, tolerability and safety of anagrelide hydrochloride versus hydroxyurea in high-risk patients with essential thrombocythaemia.
en randomiseret fase iiib undersøgelse til sammenligning af virkning, tolerans og sikkerhed for anagrelid hydroklorid vs hydroxyurea hos højrisikopatienter med essentiel trombocytæmi.